Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial

Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial

This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.

Patients with low-risk prostate cancer will receive HDR-Brachytherapy: 2 x 13,5 Gy.

Inclusion Criteria:

• Age > 18
• Histologically confirmed prostate cancer
• Gleason Score of index lesion ≤ 6 (3+3)
• Tumor stage: cT1-2a cN0 cM0
• Unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant lesion contralateral. No more than 25% of the punch should be affected. Therefore a 3D-TPM-biopsy is mandatory before treatment.
• PSA ≤ 10/ng/ml
• Prostate volume < 60 m^3
• No distant metastasis
• Life expectancy > 10 years
• Informed consent

Exclusion Criteria:

• Tumor stage ≥ T2b
• Known metastasis: N+ and/or M1
• General anesthesia or peridural anesthesia is not possible
• Coagulation disorder